Table 2.
Cannabinoid/vanilloid receptor ligands as rescue compounds
| Substance | Source | Pharmacological activity | Dose μm | Protective action against | Speciesa |
|---|---|---|---|---|---|
| Anandamide (AEA) | VVBb NIDA drug supply | type 1 and type 2 cannabinoid, and vanilloid receptor agonist | 10-20 | AM-630, CP55940 | 1 (3) |
| 5 (3) | |||||
| Arachidonoyl-ethylene glycol | VVBb | type 1 and type 2 cannabinoid receptor agonist | 40 | AA-EGa (AEA), CP55940, AM-630, chlorpyrifos, arachidonoylcholine, ritanserin | 1 (13) |
| 2 (13) | |||||
| AA-EGa (AEA) | 3 (2) | ||||
| 4 (3) | |||||
| 5 (5) | |||||
| ACPA | VVBb Tocris | type 1 cannabinoid receptor agonist | 40 | AA-EGa (AEA), AM-630, chlorpyrifos | 1 (4) |
| 2 (4) | |||||
| AM-251 | Tocris | type 1 cannabinoid receptor antagonist | 10-20 | AA-EGa (AEA), CP55940, AM-630, SB366791 | 1 (6) |
| 2 (24) | |||||
| 3 (2) | |||||
| 4 (6) | |||||
| 5 (3) | |||||
| 6 (2) | |||||
| SR141716A | NIDA drug supply | type 1 cannabinoid receptor antagonist | 10 | AA-EGa (AEA), CP55940 | 1 (3) |
| AM-630 | Tocris | type 2 cannabinoid receptor antagonist | >1-2 and more | AA-EGa (AEA), SB366791 | 1 (11) |
| 2 (2) | |||||
| Arachidonoyl vanillic acid (arvanil) | VVBb | cannabinoid/vanilloid receptor agonist | 40 | AA-EGa (AEA), CP55940, WIN55212-2, SB366791, AM-630, ritanserin, cinanserin, chlorpyrifos, lipophilic derivatives of choline, retinoic acid | 1 (33) |
| 2 (44) | |||||
| 3 (2) | |||||
| 4 (6) | |||||
| 5 (22) | |||||
| 6 (2) | |||||
| AM-404 | Tocris | inhibitor of anandamide transport | 10-50 | AA-EGa (AEA), CP55940, WIN55212-2, SB366791 | 1 (22) |
| 2 (1) | |||||
| VDM-11 | Tocris | inhibitor of anandamide transport | 20-50 | AA-EGa (AEA) | 1 (3) |
| Arachidonoyl tyramine (AA-Tyr) | VVBb | analog of AM-404 | 40 | CP55940, lipophilic derivatives of choline, ritanserin | 1 (3) |
| 5 (7) | |||||
a
From commercial sources.
b
Synthesized in the laboratory of V.V. Bezuglov (Institute of Bioorganic Chemistry, Moscow, Russia).